论文部分内容阅读
近年来发现2型糖尿病与过氧化物酶增殖体活化受体(peroxisome proliferator-activated receptor,PPAR)存在着密切的联系,该受体也因此成为设计抗2型糖尿病药物的主要靶标。目前,有很多针对PPAR所设计的化合物处于临床研究阶段,现介绍这方面的进展,并阐述开发抗2型糖尿病药物所面临的困难及相应的策略。
In recent years, it has been found that there is a close relationship between type 2 diabetes and peroxisome proliferator-activated receptor (PPAR), which has become the main target for the design of anti-type 2 diabetes drugs. At present, many compounds designed for PPAR are in the clinical research stage. We will introduce the progress in this aspect and describe the difficulties in developing anti-type 2 diabetes drugs and corresponding strategies.